Shift Towards Medicare Advantage Plans Anticipated Amid Rising PDP Premiums and Decreased Options | AMCP 2024
Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy at BluePeak Advisors, highlights the expected shift of Medicare beneficiaries towards Medicare Advantage Prescription Drug (MA-PD) plans.
Due to decreasing Prescription Drug Plan (PDP) options, rising PDP premiums and the additional benefits and risk management capabilities offered by MA-PD plans, there is an expected shift toward MA-PD plans, according to Crescent Moore, Ph.D., Pharm.D., Director of Part D/Pharmacy, BluePeak Advisors.
“We're really not going to see how that membership shifts right until we get through open enrollment, but what I think we're going to see is a shift to MA-PDs because of the additional coordination of benefits,” Moore said. “MA-PDs have more avenues and mechanisms to spread out the increased financial liability and risk.”
Moore spoke today at AMCP Nexus 2024, held at the MGM Grand Conference Center in Las Vegas. She co-led a session today called, ‘CY 2025 Medicare Part D Redesign: A Medicare Odyssey.’
BluePeak Advisors is a healthcare consulting company that specializes in Medicare.
With New Drugs in the Offing, Treatment Cost of ATTR-CM Is Projected to Climb | AMCP Nexus 2024
October 16th 2024Several companies are developing new drugs to treat transthyretin amyloidosis cardiomyopathy (ATTR-CM), a formerly obscure condition that is getting an increasing amount of attention.
Read More
Health Plans Embrace Biosimilars to Reduce Costs and Improve Patient Access | AMCP Nexus 2024
October 16th 2024How health plans are implementing strategies to leverage biosimilars to lower costs for both payers and patients, according to Javier Gonzalez, Pharm.D., chief growth and commercial officer of Abarca
Read More
